About
Glaucoma
The Burden of Glaucoma
Cataract Surgery in Patients with Glaucoma and OHT
Unmet Need
BIM-IOL
System
The SpyGlass BIM-IOL System
No Specialized Training Required
Clinical Results to Date
Market
Opportunity
Study
Data
Preclinical Study
First-in-Human Clinical Trial
Phase 1/2 Clinical Trial
Phase 3 Clinical Trials
KOL
Perspectives
pipeline
About
Us
Story
Mission, Vision, Guiding Principles
Our Team
Investor Relations +
About
Glaucoma
The Burden of Glaucoma
Cataract Surgery in Patients with Glaucoma and OHT
Unmet Need
BIM-IOL
System
The SpyGlass BIM-IOL System
No Specialized Training Required
Clinical Results to Date
Market
Opportunity
Study
Data
Preclinical Study
First-in-Human Clinical Trial
Phase 1/2 Clinical Trial
Phase 3 Clinical Trials
KOL
Perspectives
pipeline
About
Us
Story
Mission, Vision, Guiding Principles
Our Team
Investor Relations +
Pioneering sustained drug delivery
for management of chronic eye disease.
SpyGlass unites glaucoma and cataract treatment
, bringing sustained drug delivery to a trusted surgical procedure.
1
Treatment Gap
Where today's treatments fall short—and why a new approach is needed.
EXPLORE THE NEED +
Our Solution
Discover how the BIM-IOL System integrates long-acting glaucoma therapy into cataract surgery.*
DISCOVER OUR TECHNOLOGY +
The Data
Review clinical data on the safety, efficacy, and durability of the
BIM-IOL
System.
VIEW THE DATA +
Where enduring vision becomes real
*
Experience the story behind enduring vision: a key opinion leader's perspective on the technology.*
About
Glaucoma
The Burden of Glaucoma
Cataract Surgery in Patients with Glaucoma and OHT
Unmet Need
BIM-IOL
System
The SpyGlass BIM-IOL System
No Specialized Training Required
Clinical Results to Date
Market
Opportunity
Study
Data
Preclinical Study
First-in-Human Clinical Trial
Phase 1/2 Clinical Trial
Phase 3 Clinical Trials
KOL
Perspectives
pipeline
About
Us
Story
Mission, Vision, Guiding Principles
Our Team
Investor Relations +
Connect With Us
Cookie Policy
Careers
Contact us
Privacy Policy
Terms & conditions
Please confirm you wish to leave
SpyGlassPharma.com
CONFIRM
CANCEL
Please confirm you wish to open the SpyGlass LinkedIn page in another window.
CONFIRM
CANCEL
Skip to content